Claims for Patent: 10,633,397

Summary for Patent: 10,633,397

Title:	Substituted polycyclic pyridone derivatives and prodrugs thereof
Abstract:	The present invention provides the following compounds having anti-viral activity. A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A1, is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl, or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A and R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle; X is CH2, S or O; R1 is each independently halogen, hydroxy, or the like; m is any integer of 0 to 2; and n is any integer of 1 to 2.
Inventor(s):	Makoto Kawai
Assignee:	Shionogi and Co Ltd
Application Number:	US16/221,733
Patent Claims:	1. A method for treating a disease caused by a virus having cap-dependent endonuclease comprising administering a compound represented by the following formula: or its pharmaceutically acceptable salt, to a patient in need thereof. 2. A method for treating influenza comprising administering a compound represented by the following formula: or its pharmaceutically acceptable salt, to a patient in need thereof. 3. A method for preventing influenza comprising administering a compound represented by the following formula: or its pharmaceutically acceptable salt, to a patient in need thereof. 4. The method of claim 1, wherein the patient is a human. 5. The method of claim 1, wherein the administering the compound comprises orally administering a dose of about 0.1 mg to 1000 mg of the compound, or its pharmaceutically acceptable salt. 6. The method of claim 5, wherein the patient is a human. 7. The method of claim 2, wherein the patient is a human. 8. The method of claim 2, wherein the administering the compound comprises orally administering a dose of about 0.1 mg to 1000 mg of the compound, or its pharmaceutically acceptable salt. 9. The method of claim 8, wherein the patient is a human. 10. The method of claim 3, wherein the patient is a human. 11. The method of claim 3, wherein the administering the compound comprises orally administering a dose of about 0.1 mg to 1000 mg of the compound, or its pharmaceutically acceptable salt. 12. The method of claim 11, wherein the patient is a human.